Research
Hormonal
Manufacturer discounts for GLP1s approved for type 2 diabetes ranged from 54% to 59%, leading to net prices of $312 to $469 per month of supply.
Practitioners should be aware of the cost implications of GLP1s for type 2 diabetes when advising patients.
StrongSupportsmedium confidence
Manufacturer discounts for GLP1s approved for type 2 diabetes ranged from 54% to 59%, which translated into net prices of $312 to $469 per month of supply.
Why this rating
The claims are based on a peer-reviewed estimation method.
Source
Net prices of new antiobesity medications
Inmaculada Hernandez et al. · Obesity · 2024
DOI 10.1002/oby.23973
otherCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →